Literature DB >> 16705777

Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII.

Walter H Dzik1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16705777     DOI： 10.1177/0885066605285223

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN： 0885-0666            Impact factor:   3.510


× No keyword cloud information.
  4 in total

1.  Comparative effectiveness: the employer perspective.

Authors:  Marc B Royo
Journal:  Biotechnol Healthc       Date:  2009-08

Review 2.  [Management of hemostasis disorders after extracorporeal circulation. A clinical therapy algorithm].

Authors:  C Jámbor; D Bremerich; A Moritz; E Seifried; B Zwissler
Journal:  Anaesthesist       Date:  2008-04       Impact factor: 1.041

3.  Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage.

Authors:  Yoan Lamarche; Philippe Demers; Nancy C Poirier; Danielle Robitaille; Raymond Cartier
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

Review 4.  The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework.

Authors:  Y Lin; C J Moltzan; D R Anderson
Journal:  Transfus Med       Date:  2012-05-27       Impact factor: 2.019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.